Anticipated Newsflow

Product   Target Achieved  Date 
US Commercial
CCP-07 :  Single dose PK study results                2016 P  Dec 2015
CCP-07 : Multiple dose PK study results 2016 P Apr 2016
CCP-08 :  Single dose PK study results 2016 P Apr 2016
CCP-08 : Multiple dose PK study results 2016 P  Jul 2016
CCP-07 :  NDA submission 2016 P Sep 2016 
Moxatag® :  Launch 2016 P
Oct 2016
CCP-08 :  NDA submission 2016 P  Dec 2016
CCP-07 : Potential FDA Approval Q2 2017    
CCP-08 :  Potential FDA Approval Q3 2017    
CCP-05 :  Target POC By end of Financial Year 2017    
CCP-06 : Target POC By end of Financial Year 2017   
 
 
 
         
         
         

 

 

 

 

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch